Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe
  • Home
  • fibromyalgia
Optimizing Value in Fibromyalgia Care: High-Dose Duloxetine and Pregabalin Outperform Amitriptyline in Lifetime Cost-Effectiveness Models
Posted innews Psychiatry Rheumatology

Optimizing Value in Fibromyalgia Care: High-Dose Duloxetine and Pregabalin Outperform Amitriptyline in Lifetime Cost-Effectiveness Models

Posted by MedXY By MedXY 02/06/2026
A recent decision analytical model identifies duloxetine 120 mg as the most cost-effective treatment for moderate-to-severe fibromyalgia, providing superior clinical outcomes at a marginal cost increase compared to amitriptyline, particularly when societal impacts are considered.
Read More
FDA Approves Tonmya: First Nonopioid Sublingual Treatment Targeting Sleep in Fibromyalgia
Posted inNeurology news Specialties

FDA Approves Tonmya: First Nonopioid Sublingual Treatment Targeting Sleep in Fibromyalgia

Posted by MedXY By MedXY 08/19/2025
The FDA has approved Tonmya (sublingual cyclobenzaprine) as the first new fibromyalgia therapy in 15 years, targeting nonrestorative sleep to alleviate pain, fatigue, and cognitive symptoms in adults.
Read More
  • Redefining the Standard of Care in High-Risk Resected SCCHN: Insights from the GORTEC 2018-01 NIVOPOST-OP Trial
  • Savolitinib Plus Osimertinib Redefines Second-Line Therapy for MET-Amplified, EGFR-Mutant NSCLC: Insights from the Phase 3 SACHI Trial
  • Fractional Yellow Fever Vaccination Fails Non-Inferiority in Infants: Why Adult Data Cannot Be Extrapolated to Pediatric Populations
  • AI-Supported Mammography Outperforms Standard Double Reading: Insights from the MASAI Trial
  • Ensitrelvir Demonstrates Potent Antiviral Efficacy Comparable to Nirmatrelvir in Early COVID-19: Insights from the PLATCOV Trial
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号

  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular health cardiovascular risk chronic kidney disease clinical trial clinical trials critical care depression diabetes epidemiology exercise health heart failure Hypertension immunotherapy inflammation MASLD mental health metformin Mortality nutrition obesity older adults oncology Pediatrics Physical Activity precision medicine Pregnancy prevention prostate cancer public health randomized clinical trial randomized trial SGLT2 inhibitors stroke targeted therapy type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top
Sign in